Gibson Dunn Represents RTW Investments in Acquisition of Synthetic Royalty Interest in Anaphylm™

Gibson Dunn is advising RTW Investments, LP in its acquisition from Aquestive Therapeutics, Inc of a synthetic royalty interest in Anaphylm™ (epinephrine) Sublingual Film, and in its acquisition of Aquestive common stock.